In fact, recently, patisiran represents the world’s first siRNA-based drug that is FDA-approved for the treatment of hereditary transthyretin-mediated amyloidosis via transthyretin (TTR) gene silencing [311]. The gene discussed is TTR; the disease is amyloidosis.